首页> 美国卫生研究院文献>Journal of Korean Medical Science >Predictors of Pulmonary Function Response to Treatment with Salmeterol/fluticasone in Patients with Chronic Obstructive Pulmonary Disease
【2h】

Predictors of Pulmonary Function Response to Treatment with Salmeterol/fluticasone in Patients with Chronic Obstructive Pulmonary Disease

机译:沙美特罗/氟替卡松治疗对慢性阻塞性肺疾病患者肺功能反应的预测指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and responses to therapies are highly variable. The aim of this study was to identify the predictors of pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD. A total of 127 patients with stable COPD from the Korean Obstructive Lung Disease (KOLD) Cohort, which were prospectively recruited from June 2005 to September 2009, were analyzed retrospectively. The prediction models for the FEV1, FVC and IC/TLC changes after 3 months of treatment with salmeterol/fluticasone were constructed by using multiple, stepwise, linear regression analysis. The prediction model for the FEV1 change after 3 months of treatment included wheezing history, pre-bronchodilator FEV1, post-bronchodilator FEV1 change and emphysema extent on CT (R = 0.578). The prediction models for the FVC change after 3 months of treatment included pre-bronchodilator FVC, post-bronchodilator FVC change (R = 0.533), and those of IC/ TLC change after 3 months of treatment did pre-bronchodilator IC/TLC and post-bronchodilator FEV1 change (R = 0.401). Wheezing history, pre-bronchodilator pulmonary function, bronchodilator responsiveness, and emphysema extent may be used for predicting the pulmonary function response to 3 months of treatment with salmeterol/fluticasone in patients with COPD.
机译:慢性阻塞性肺疾病(COPD)是一种异质性疾病,对治疗的反应差异很大。这项研究的目的是确定COPD患者沙美特罗/氟替卡松治疗3个月后肺功能反应的预测因子。回顾性分析了2005年6月至2009年9月期间从韩国阻塞性肺疾病(KOLD)队列收集的127例稳定的COPD患者。通过使用多元逐步线性回归分析,建立了沙美特罗/氟替卡松治疗3个月后FEV1,FVC和IC / TLC变化的预测模型。治疗3个月后FEV1变化的预测模型包括喘息史,支气管扩张剂前FEV1,支气管扩张剂后FEV1变化和CT气肿程度(R = 0.578)。治疗3个月后FVC变化的预测模型包括支气管扩张剂前FVC,支气管扩张剂后FVC变化(R = 0.533),治疗3个月后IC / TLC变化的模型包括支气管扩张剂前IC / TLC和术后-支气管扩张剂FEV1改变(R = 0.401)。喘息史,支气管扩张剂前肺功能,支气管扩张剂反应性和肺气肿程度可用于预测COPD患者沙美特罗/氟替卡松治疗3个月后的肺功能反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号